HomeAI · summaries
Storia in 6 fonti
FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes
The FDA has granted accelerated approval for teplizumab-mzwv as the first disease-modifying therapy for children and adolescents with stage 3 type 1 diabetes, according to an industry press release. As Healio previously reported, teplizumab-mzwv (Tzield, Sanofi) was originally approved by the FDA in November 2022 to delay stage 3 type 1 diabetes among children and adults with stage 2 disease. In
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
- ·
thehindubusinessline.com
US FDA approves expanded use of Sanofi's type 1 diabetes drug
The FDA approves Sanofi’s Tzield for type 1 diabetes, now available for children aged 8-17 recently diagnosed with stage 3.
